

12530

PHASE I/II ALKOVE-1 STUDY OF NVL-655 IN ALK-POSITIVE (ALK+) SOLID TUMOURS

1256MO

PHASE I/II ARROS-1 STUDY OF ZIDESAMTINIB (NVL-520) IN ROS1 FUSION-POSITIVE SOLID TUMOURS

LBA8

PRECISION IMMUNO-ONCOLOGY FOR ADVANCED NON-SMALL CELL LUNG CANCER (**NSCLC**) PATIENTS WITH PD-(L)1 INHIBITORS RESISTANCE (PIONEER): A PHASE IB/IIA CLINICAL TRIAL TARGETING IDENTIFIED RESISTANCE PATHWAYS

LBA48

CCTG BR.31: A GLOBAL, DOUBLE-BLIND PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF ADJUVANT DURVALUMAB IN COMPLETELY RESECTED NON-SMALL-CELL LUNG CANCER (**NSCLC**)

LBA54

AMIVANTAMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN EGFR-MUTATED, ADVANCED NON-SMALL CELL LUNG CANCER (**NSCLC**) AFTER DISEASE PROGRESSION ON OSIMERTINIB: 2ND INTERIM OVERALL SURVIVAL FROM MARIPOSA-2

1241MO

OSIMERTINIB (OSI) AFTER DEFINITIVE CHEMORADIOOTHERAPY (CRT) IN UNRESECTABLE (UR) STG III EGFRM **NSCLC**: ANALYSES OF CNS AND DISTANT PROGRESSION FROM THE PHASE III LAURA

1207MO

NEOADJUVANT NIVOLUMAB MONOTHERAPY FOR HIGH-RISK CLINICAL STAGE I NON-SMALL CELL LUNG CANCER (**NSCLC**): A PHASE II POTENTIAL

1257MO

ABBV-400, A C-MET PROTEIN-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS (PTS) WITH ADVANCED EGFR WILDTYPE (WT) NON-SQUAMOUS (NSQ) NON-SMALL CELL LUNG CANCER (**NSCLC**)

LBA83

PECATI: A PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB IN PRETREATED ADVANCED B3-**THYMOMA** AND **THYMIC CARCINOMA**

**LBA
52**

INTERIM ANALYSIS OF GALAXIES LUNG-201: PHASE II, RANDOMIZED, OPEN-LABEL PLATFORM STUDY OF BELRESTOTUG PLUS DOSTARLIMAB IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED/METASTATIC (LA/M) PD-L1 HIGH (TPS \geq 50%) NON-SMALL CELL LUNG CANCER (**NSCLC**)

Leads



Dr Horinouchi
Med Onc



Dr Ricciuti
Med Onc



Dr Singhi
Med Onc



Dr Morgan
Clin Onc

Faculty



Dr Popat
Med Onc



Dr Liu
Med Onc



Dr Aggarwal
Med Onc



Dr Lopes
Med Onc



Dr Naidoo
Med Onc